Products & Services

View All Products ❯

Pre-Transplant

HLA Typing AllType NGS Genotyping LABType Lambda Monoclonal Trays (LMT) LinkSeq Typing Micro SSP SeCore Serology Reagents Tissue Typing Trays

Antibody Detection AT1R & ETAR C1qScreen FlowDSA-XM FlowPRA LABScreen Lambda Antigen Tray (LAT) Lambda Cell Tray (LCT)

Post-Transplant

Antibody Monitoring

Cell-free DNA

Chimerism

Gene Expression Profiling

Companion Diagnostics

SeCore CDx

Transfusion

Blood Screening

Blood Typing

Software Automation

Instruments

Customer Care

Products & Support Files

Technical Product Support

Documentation & Software

Knowledge Base Articles

RSS Feeds

Learning Center

Educational Programs

Recorded Events

Scientific Research

Video Tutorial Service

MMDx Resource Library

Patient Resource Library

Company

Events

Community News

Distributors

Holidays

Our Mission

Patient Advocacy

Recent searches Clear History

Suggestions

All Results

Devyser and Thermo Fisher Scientific Expand Commercial Agreement to Brazil

Devyser and Thermo Fisher Scientific Logos

Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil.

"We are very excited to enter into this agreement. Up to now, our products have not been available in the large Brazilian market, and we are highly optimistic about future sales in the country, which has the second-highest number of transplanted organs globally. The agreement provides laboratories in Brazil access to genetic tests that are simple, fast, and easy to use. We are convinced that Thermo Fisher, the leading innovator in the HLA industry, will do this very successfully"

Fredrik Alpsten | CEO at Devyser

In Brazil, a total of approximately 6,000 kidneys are transplanted every year. Only the US has a higher number of transplantations. The agreement includes One Lambda Devyser Chimerism for early detection of graft rejection in stem cell transplanted patients and One Lambda Devyser Accept cfDNA, a novel test for detecting donor-derived cell-free DNA in blood samples from kidney transplant patients.

Article published: 2023 September 6